Aurobindo gets USFDA nod to market generic Osteoporosis drug

01 Dec 2015


Aurobindo PharmaBSE 1.80 % has confirmed that it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of osteoporosis, in the American market. 
Economic Times


Share this story